Lymphoma & Myeloma Clinical Trials

Lymphoma Screening for Providers

https://is.gd/LymphomaScreening

Lymphoma Clinical Trials

Last Updated: 2/22/2019

CAR T/Cellular Therapy

2017-0161 (ZUMA-9): A Multicenter, Open-Label, Expanded Access Study of Axicabtagene Ciloleucel For The Treatment of Relapsed/Refractory Transplant-Ineligible Aggressive Non-Hodgkin Lymphoma (NHL)

2017-0055 (ZUMA-5): A Phase 2 Multicenter Study of  axicabtagene ciloleucel in subjects with relapsed/refractory indolent non-hodgkin lymphoma

2017-0699 (ZUMA-7): A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)

2018-0373 (UNUM): Phase 1 Study of ACTR707, an Autologous T Cell Product, in Combination with Rituximab, in Subjects with Relapsed or Refractory CD20+ B Cell Lymphoma

2015-0529 (CAR T-cells): Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)

2018-0580 (ZUMA-12): A Phase 2 Multicenter Study Evaluating the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma (ZUMA-12)

2015-0372 (KTE-C19): Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

2017-0730 ( JCAR017): An Exploratory Phase 1/2 Trial To Evaluate The Safety And Efficacy Of JCAR017 Combinations In Subjects With Relapsed/Refractory B-Cell Malignancies (PLATFORM)

 

Myeloma CAR T

2017-0444 (P-BCMA-101):  Open-Label, Multicenter, Single Ascending Dose Study to Assess the Safety of P-BCMA-101 in Subjects with Relapsed and/or Refractory Multiple Myeloma (MM)

 

Indolent Lymphoma (Follicular, Marginal Zone, Small Lymphocytic Leukemia)

Newly Diagnosed

2017-0859 (Vitamin D): A Phase III Double Blind, Prospective Randomized Trial to Evaluate the Supplemental Effect of Vitamin D (Cholecalciferol) on Progression-Free Survival in Patients with Low Tumor-Burden Indolent Non-Hodgkin Lymphoma Treated with Rituximab Therapy

2015-0464 (obinutuzmab + lenalidomide): An Open Label, Phase 2 study of Obinutuzumab and Lenalidomide in Previously Untreated Subjects with Follicular Lymphoma

2017-0064 (ibrutinib + rituximab): Phase 3 Study of Ibrutinib with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma

Previously Treated

2017-0859 (Vitamin D):  A Phase III Double Blind, Prospective Randomized Trial to Evaluate the Supplemental Effect of Vitamin D (Cholecalciferol) on Progression-Free Survival in Patients with Low Tumor-Burden Indolent Non-Hodgkin Lymphoma Treated with Rituximab Therapy

2017-1063 (LAM-002) A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A (apilimod dimesylate capsules) Administered Orally in Subjects with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

2013-0261 (Len+ Obinutuzumab):  Phase I/II study of Lenalidomide and Obinutuzumab (GA101) in Relapsed Indolent Non-Hodgkin Lymphoma

2017-0440 (UBL+TGR-1202): A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin Lymphoma

2017-0141 (BTCT4465):  An Open-label, Multicenter, Phase I/Ib Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of BTCT4465A as a Single Agent and Combined with Atezolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma And Chronic Lymphocytic Leukemia

2017-1007 (BGB311): An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined with Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/Refractory Follicular Lymphoma

2017-1063 (LAM-002A):  A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A (apilimod dimesylate capsules) Administered Orally in Subjects with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

2014-0541 (Phase 1b/2): An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects with B-cell Non-Hodgkin Lymphoma

2014-0539 (ACP-196): Phase II study of rituximab plus pembrolizumab (MK-3475) in subjects with relapsed follicular lymphoma

2016-0034 (MK-3475): A Phase II study to determine feasibility and safety of single agent MK-3475 in relapsed or refractory Peripheral T-cell Non-Hodgkin lymphoma

2017-0440 (UBL+TGR-1202): A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combinationof Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone inPatients with Previously Treated Non-Hodgkin Lymphoma

Diffuse Large B-Cell Lymphoma

Newly Diagnosed 

2015-0147 (Ritux /Lenalid / Ibrutinib + Chemo): Phase I/II Study of Lenalidomide and Obinutuzumab with CHOP for Diffuse Large B Cell Lymphoma

 Previously Treated 

2017-1063 (LAM-002A): A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A (apilimod dimesylate capsules) Administered Orally in Subjects with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

2015-0022: Pilot Project for Creation of the DLBCL Response Prediction Model: Combining Early Interim Functional Imaging, Detection Of A Tumor-Specific Clonotype and Metabolic Profiling of Blood Of In Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma To Predict Response To Standard Immunochemotherapy

2017-0626 (ASTX660): Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas

2015-0569 (Based CD19): Long Term Follow-Up of Patients Exposed to Lentiviral- Based CD19 directed CART Cell Therapy

2017-0475 (UC-961): A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with B-Cell Lymphoid Malignancies

2017-0025 (DA-EPOCH): Phase I Study of Venetoclax plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas

2018-0510 (NIVO): Nivolumab and Ibrutinib for Relapsed or Refractory Central Nervous System Lymphoma

Hodgkin lymphoma

Previously Treated 

2018-0114 ( PET-AVD): A Phase II Trial of PET-Directed Therapy using AVD (doxorubicin, vinblastine, and dacarbazine) plus Brentuximab Vedotin Induction Chemotherapy, with or without Brentuximab Vedotin plus Nivolumab, Followed by Nivolumab Consolidation for Patients with Previously Untreated Non-bulky Limited Stage Hodgkin Lymphoma

2017-0731 (PD-1 + ICE): A phase II trial of response-adapted second-line therapy for Hodgkin lymphoma using anti-PD-1 antibody nivolumab +/- ICE chemotherapy as a bridge to autologous hematopoietic cell transplant (NICE Trial)

2017-0974 (CheckMate 812):  Randomized, Open-label, Phase 3 Trial of Nivolumab plus Brentuximab vedotin versus Brentuximab vedotin alone in Participants with Relapsed Refractory or Ineligible for Autologous Stem Cell Transplant (ASCT) Advanced Stage Classical Hodgkin Lymphoma (CheckMate 812: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 812)

2016-0423 (Nivo +Brent):  Phase II, Multi-center Trial of Nivolumab and Brentuximab Vedotin in Patients with Untreated Hodgkin Lymphoma Over the Age of 60 Years or Unable to Receive Standard Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) Chemotherapy

2015-0160 (ADCT-301):  A Phase 1 Adaptive Dose-Escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-301 in Patients with Relapsed or Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma

 

Mantle Cell Lymphoma 

Newly Diagnosed

2017-0141 (BTCT4465): An Open-label, Multicenter, Phase I/Ib Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of BTCT4465A as a Single Agent and Combined with Atezolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma And Chronic Lymphocytic Leukemia

2013-0090 (Ibrutinib + Rituximab): Phase II Study of Ibrutinib Plus Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma or Elderly Patients with Newly Diagnosed MCL

2016-1048 (ACP-196): A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Verses in Combination with Acalabrutinib (ACP-196) in Subjects With Previously Untreated Mantle Cell Lymphoma

Previously Treated

2015-0663 (Akt and ERK inhibitor): A Phase I, Open-Label, Multiple-Dose, Dose Escalation and Expansion Study to Investigate the Safety and Pharmacokinetics of the BTK Inhibitor BGB-3111 in Subjects with B-Cell Lymphoid Malignancies

2014-0559 (Rit+H-CVAD): A Phase II Study of Ibrutinib plus Rituximab with Hyper-CVAD Consolidation in Newly Diagnosed Young Patients with Mantle Cell Lymphoma: A Window Period for Bioimmunotherapy before Chemotherapy

2014-0630 (Akt and ERK inhibitor): Phase I/II Study of Oral ONC201 in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

2012-1107 (2010-0837) (PCI-32765):Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

2017-0238 (Ibrutinib + Venetoclax): Phase 3 Study of Ibrutinib in Combination with Venetoclax in Subjects with

2017-0301 (AZD5991): A Phase 1, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD5991 in Subjects with Relapsed or Refractory Haematologic Malignancies

Burkitt's Lymphoma

Newly Diagnosed

 

Previously Treated 

 

Peripheral T-Cell Lymphoma

Newly Diagnosed

2015-0555 (Folotyn®): Phase 1, Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients with Peripheral T-Cell Lymphoma (PTCL)

2013-0367 Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Patients with Stage I/II Nasal NK Cell Lymphoma

Previously Treated

2017-0626 (ASTX660): Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas

2017-0927 (CHEP-BV): A Phase 2 Study of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients with CD30-Positive Peripheral T-cell Lymphomas

2017-0272 (MK-3475): A phase I/II study of pembrolizumab (MK-3475) in combination with romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma

 

Multiple Myeloma Clinical Trials

Myeloma CAR T/Cellular Therapy

2017-0444 (P-BCMA-101):  Open-Label, Multicenter, Single Ascending Dose Study to Assess the Safety of P-BCMA-101 in Subjects with Relapsed and/or Refractory Multiple Myeloma (MM)

Myeloma

2017-0618 (CC-92480 +Dex in R/R MM): A Phase I Multicenter, Open-label study to assess the Safety, Pharmacokinetics and Preliminary Efficacy of CC-92480 in combination with Dexamethasone in Subjects with Relapsed and Refractory Multiple Myeloma

2018-0512 (D+B-Dex in R/R MM): A Phase 2 Study of Daratumumab, Bortezomab and Dexamethasone followed by Daratumumab, Ixaazomib, and  Dexamethasone for Relapsed/Refractory Myeloma

2018-0345 (Vaccine): A Personalized Vaccine for the Immune Prevention of Multiple Myeloma

2016-0225 (c-Met Inh): A Phase I/II Study of the c-Met Inhibitor Cabozantinib as a Targeted Strategy to Reverse Resistance to the Proteasome Inhibitor Carfilzomib in Refractory Multiple Myeloma

2018-0192 (XmAb13676): A Phase 1 Multidose Study to Evaluate the Safety and Tolerability of XmAb13676 in Patients with CD20-Expressing Hematologic Malignancies

2015-0148 (SAR650984): Phase II single arm trial of SAR650984 in patients with intermediate and high risk smoldering multiple myeloma

2017-0024 (MIK665 (Mcl-1) inhibitor: Phase I open label, multi-center study to characterize the safety, tolerability and pharmacokinetics of intravenously administered MIK665, a Mcl-1 inhibitor, in patients with refractory or relapsed lymphoma or multiple myeloma

2017-1022 (IDd): A Phase 2, Open-Label Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)

2018-0369 (DREAMM 2): A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the Efficacy and Safety of Two Doses of the Antibody Drug Conjugate GSK2857916 in Participants with Multiple Myeloma Who Had 3 or More Prior Lines of Treatment, Are Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent and Have Failed an Anti-CD38 Antibody (DREAMM 2)

2017-0935 (SAR650984): A Phase 3 randomized, open label, multicenter study assessing the clinical benefit of isatuximab (SAR650984) in combination with bortezomib (Velcade®), lenalidomide (Revlimid®) and dexamethasone versus bortezomib, lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not eligible for transplant

2015-0101 (DS-3032b):  Phase I Ascending Dose and Exploratory Expansion Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects with Relapsed and/or Refractory Multiple Myeloma

2017-1058 (TAK-079):  A Phase 1/2a Open-label, Dose-Escalation Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Patients With Relapsed/Refractory Multiple Myeloma

2017-1012 (AMG 701):  A Phase 1 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 701 in Subjects With Multiple Myeloma

2017-0243 (AL AMY):  A Safety Study of Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis

NCI10076 (AM232):  A Phase 1 Dose-Escalation and Exploratory Dose Expansion Study of AMG 232 in Combination with Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed and/or Refractory Myeloma

2017-0408 (CyBorD):  A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis

Lab10-0774 (Elotuzumab + Lenalidomide):  Phase II Study of the combination of Elotuzumab with Lenalidomide as Maintenance Therapy post Autologous Stem Cell Transplant in Patients with Multiple Myeloma

2014-0729 (Elotuzumab + Lenalidomide):  Phase II Study of the combination of Elotuzumab with Lenalidomide as Maintenance Therapy post Autologous Stem Cell Transplant in Patients with Multiple Myeloma